Colorado Antimicrobial Regeneration Consortium

Accelerating Research and Development for Countering Drug-Resistant Pathogens

Antimicrobial resistance is a major health crisis humanity faces today affecting both high and low-income countries. The emergence of superbugs, a shrinking pipeline of antibiotics, and ineffective therapy underscores the need for new antibiotics and new antibiotic classes. In 2013, the CDC estimated that more than 2 million people were infected by antibiotic-resistant infections each year in the US alone, with at least 23,000 deaths as a result of those infections. An alarming estimate is that if unchecked super bugs will be responsible for more than 10 million deaths each year by 2050, far outpacing all other major causes like diabetes, cancer, and road accidents, and its economic impact will reach $100 trillion by 2050.

Antimicrobial Regeneration Consortium

The goal of Antimicrobial Regeneration Consortium (ARC) is to implement a rapid antibiotic development pipeline to enable high-throughput discovery of therapeutics capable of targeting any current or emerging pathogens. ARC is designed to respond to the global health issue of antimicrobial resistance by accelerating drug research from start to finish through minimizing time required for fund-raising, maximizing researchers’ time for investigation, and providing a pathway for fast translation to clinic. With an innovative and interdisciplinary approach to medicine, ARC Labs envisions that one day we will be able to respond to emerging health threats in real-time. Our efforts are designed to handle the extreme, providing a response to current and potential future health crises.

A Collaboration Across Colorado

While ARC is a global effort, Colorado ARC (CO-ARC) adapts the model to address antimicrobial resistance regionally in Colorado. Through a new partnership with the University of Colorado Boulder, ARC is nucleating a Colorado-wide network of scientists, doctors, and community members who collaborate in the face of antimicrobial resistance. The ARC model will be implemented to serve the needs of Colorado while maintaining a strong connection with the global effort at large. A response to the global challenge of antimicrobial resistance demands efforts at every level of community; CO-ARC is Colorado's answer to antimicrobial resistance.

This effort aims to build a joint center initiative to spur biomedical research within the state of Colorado for development of antimicrobials and precision diagnostics. CO-ARC will create a research corridor by establishing major partnerships between University of Colorado Boulder, University of Colorado Denver and Anschutz Medical School, Colorado State University, and Centers of Disease Control and Prevention at Fort Collins.

News & Updates

CO-ARC Scientists Featured in News Around the World

CU Boulder Developing Therapeutics to Counter Antibiotic-Resistant Bacteria

Ideas To Fight the End of Antibiotics